Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerHumansPemetrexedDexamethasoneMaleFemale
Younger age as a risk factor for rash development in pemetrexed and carboplatin treatment with dexamethasone prophylaxis.
Yoshitaka Saito, Osamu Taniguchi, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara
Published: 202510.1007/s00520-025-09953-1
Abstract
PURPOSE: Carboplatin (CBDCA) plus pemetrexed (PEM) is one of the most effective regimens for treating thoracic cancer. Rash, which is mainly caused by PEM, occurs in 15-30% of patients. Dexamethasone administration for 3 days is recommended to manage…
Preview only. Read the full abstract at the source